Progyny (NASDAQ:PGNY - Get Free Report) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.440-0.470 for the period, compared to the consensus earnings per share estimate of 0.400. The company issued revenue guidance of $300.0 million-$318.0 million, compared to the consensus revenue estimate of $280.5 million. Progyny also updated its FY 2025 guidance to 1.520-1.620 EPS.
Progyny Stock Performance
Shares of PGNY traded down $0.53 during midday trading on Monday, hitting $22.00. 3,660,909 shares of the company traded hands, compared to its average volume of 1,537,778. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of 37.93, a PEG ratio of 2.39 and a beta of 1.34. The firm has a 50 day moving average of $20.83 and a 200-day moving average of $18.67. Progyny has a 52 week low of $13.39 and a 52 week high of $38.98.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on PGNY shares. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Canaccord Genuity Group increased their target price on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday. Truist Financial restated a "hold" rating and issued a $19.00 price target (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Barclays lowered their price objective on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $24.82.
Check Out Our Latest Analysis on PGNY
Insider Buying and Selling
In other Progyny news, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman David J. Schlanger bought 150,000 shares of the firm's stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.
About Progyny
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Recommended Stories
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
